Breakdown | TTM | Dec 2025 | Dec 2023 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 15.51B | 15.51B | 14.18B | 13.66B | 14.10B | 13.52B |
Gross Profit | 7.40B | 7.40B | 1.59B | 5.53B | 5.66B | 6.15B |
EBITDA | 1.70B | 1.59B | -464.48M | 549.80M | 1.18B | 2.06B |
Net Income | 218.80M | 218.80M | -1.21B | -358.69M | 409.55M | 954.42M |
Balance Sheet | ||||||
Total Assets | 16.02B | 16.02B | 15.29B | 15.40B | 14.51B | 13.93B |
Cash, Cash Equivalents and Short-Term Investments | 691.40M | 691.40M | 416.25M | 687.85M | 591.21M | 597.03M |
Total Debt | 4.81B | 4.81B | 4.44B | 4.88B | 3.65B | 2.77B |
Total Liabilities | 8.32B | 8.32B | 7.80B | 8.27B | 7.11B | 6.16B |
Stockholders Equity | 7.04B | 7.04B | 6.99B | 6.57B | 6.92B | 7.28B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | 442.70M | -693.71M | -2.12M | -18.69M | 619.24M |
Operating Cash Flow | 0.00 | 833.60M | 168.08M | 305.95M | 305.95M | 1.15B |
Investing Cash Flow | 0.00 | -247.80M | -649.58M | -119.05M | -955.66M | 96.48M |
Financing Cash Flow | 0.00 | -607.30M | 322.28M | 45.46M | 672.57M | -1.39B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | ₹37.92B | 27.71 | 1.54% | 5.89% | -1.30% | ||
66 Neutral | ₹43.29B | 23.69 | 0.21% | -0.03% | 21.33% | ||
54 Neutral | ₹44.38B | 149.25 | ― | 12.33% | 439.46% | ||
54 Neutral | ₹561.75B | 75.08 | 0.13% | 10.99% | ― | ||
51 Neutral | $7.92B | -0.43 | -41.69% | 2.21% | 22.29% | -1.85% | |
41 Neutral | ₹46.75B | ― | ― | -5.57% | 23.03% | ||
― | ₹48.22B | ― | ― | ― | ― |
Sequent Scientific Limited has published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, in two newspapers, The Financial Express and Nava Telangana. This announcement is part of the company’s compliance with regulatory requirements, providing stakeholders with insights into its financial performance for the specified period.